文献速递妇科

非唑奈坦治疗绝经相关血管舒缩症状的安全性:一项随机对照试验

Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial.
PubMed 文献 · Obstet Gynecol · 2023-03-09

这项3期随机双盲52周安全性研究纳入1830名绝经后血管舒缩症状女性,按1:1:1接受安慰剂、非唑奈坦30 mg或45 mg每日一次。结果显示治疗中出现的不良事件率三组相似,子宫内膜增生或恶性肿瘤发生率低,肝酶升高无Hy's law病例,骨密度和骨小梁评分变化相似,证实非唑奈坦52周安全性和耐受性。

要点

  • 治疗中出现的不良事件率:安慰剂64.1%、非唑奈坦30 mg组67.9%、45 mg组63.9%。
  • 子宫内膜增生:45 mg组1/203(0.5%,单侧95%CI上限2.3%),安慰剂和30 mg组均为0例。
  • 子宫内膜恶性肿瘤:30 mg组1/210(0.5%,95%CI 2.2%),其他组无病例。

核心结论

  • SKYLIGHT 4结果证实非唑奈坦52周安全性和耐受性,并支持其继续开发。

研究设计与样本

  • 3期随机双盲52周安全性研究(SKYLIGHT 4),比较安慰剂、非唑奈坦30 mg和45 mg每日一次(1:1:1)。
  • 参与者为绝经后寻求绝经相关血管舒缩症状治疗的女性,共1830名随机并至少服用一次药物(2019年7月至2022年1月)。
  • 主要终点为治疗中出现的不良事件、子宫内膜增生百分比和子宫内膜恶性肿瘤百分比,子宫内膜增生或恶性肿瘤按美国食品药品监督管理局指南评估(点估计≤1%且单侧95%CI上限≤4%)。
  • 次要终点包括骨密度和骨小梁评分变化,计算样本量1740例以观察一个或多个事件(背景率<1%的事件约80%概率)。

主要发现

  • 治疗中出现的不良事件:安慰剂组64.1%(391/610)、非唑奈坦30 mg组67.9%(415/611)、45 mg组63.9%(389/609)。
  • 导致停药的治疗中出现的不良事件:安慰剂组26/610(4.3%)、30 mg组34/611(5.6%)、45 mg组28/609(4.6%)。
  • 子宫内膜安全性评估599例:45 mg组203例中1例子宫内膜增生(0.5%;单侧95%CI上限2.3%),安慰剂组0/186、30 mg组0/210无病例。
  • 子宫内膜恶性肿瘤:30 mg组210例中1例(0.5%;95%CI 2.2%),其他组无病例。
  • 肝酶升高超过正常上限3倍:安慰剂组6/583、30 mg组8/590、45 mg组12/589;无Hy's law病例报告。

关键数值与推荐

  • 子宫内膜增生或恶性肿瘤评估标准:点估计≤1%且单侧95%CI上限≤4%(美国食品药品监督管理局指南)。
  • 子宫内膜增生:45 mg组0.5%(单侧95%CI上限2.3%),符合上述标准。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety, tolerability, and effect of fezolinetant on endometrial health over 52 weeks. METHODS: We conducted a phase 3, randomized, double-blind, 52-week safety study (SKYLIGHT 4 [Study to Find Out How Safe Long-term Treatment With Fezolinetant is in Women With Hot Flashes Going Through Menopause]) of placebo, fezolinetant 30 mg, and fezolinetant 45 mg once daily (1:1:1). Participants were postmenopausal and seeking treatment for vasomotor symptoms associated with menopause. Primary endpoints were treatment-emergent adverse events, percentage of participants with endometrial hyperplasia, and percentage with endometrial malignancy. Endometrial hyperplasia or malignancy was evaluated according to U.S. Food and Drug Administration guidance (point estimate of 1% or less with an upper bound of one-sided 95% CI of 4% or less). Secondary endpoints included change in bone mineral density (BMD) and trabecular bone score. A sample size of 1,740 was calculated to enable observation of one or more events (≈80% probability for events with background rate of less than 1%). RESULTS: A total of 1,830 participants were randomized and took one or more medication dose (July 2019-January 2022). Treatment-emergent adverse events occurred in 64.1% (391/610) of the placebo group, 67.9% (415/611) of the fezolinetant 30-mg group, and 63.9% (389/609) of the fezolinetant 45-mg group. Treatment-emergent adverse events leading to discontinuation were similar across groups (placebo, 26/610 [4.3%]; fezolinetant 30 mg, 34/611 [5.6%]; fezolinetant 45 mg, 28/609 [4.6%]). Endometrial safety was assessed in 599 participants. In the fezolinetant 45-mg group, 1 of 203 participants had endometrial hyperplasia (0.5%; upper limit of one-sided 95% CI 2.3%); there were no cases in the placebo (0/186) or fezolinetant 30 mg (0/210) group. Endometrial malignancy occurred in 1 of 210 in the fezolinetant 30-mg group (0.5%; 95% CI 2.2%) with no cases in the other groups. Liver enzyme elevations more than three times the upper limit of normal occurred in 6 of 583 placebo, 8 of 590 fezolinetant 30 mg, and 12 of 589 fezolinetant 45 mg participants; no Hy's law cases were reported (ie, no severe drug-induced liver injury with alanine aminotransferase or aspartate aminotransferase more than three times the upper limit of normal and total bilirubin more than two times the upper limit of normal, with no elevation of alkaline phosphatase and no other reason to explain the combination). Changes in BMD and trabecular bone score were similar across groups. CONCLUSION: Results from SKYLIGHT 4 confirm the 52-week safety and tolerability of fezolinetant and support its continued development. FUNDING SOURCE: Astellas Pharma Inc. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov , NCT04003389.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Neal-Perry G, Cano A, Lederman S, et al. Safety of Fezolinetant for Vasomotor Symptoms Associated With Menopause: A Randomized Controlled Trial. Obstet Gynecol. 2023. PMID: 36897180. doi:10.1097/AOG.0000000000005114

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。